Revenue increased 307% and 87%, respectively, compared to the three and nine month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
TUCSON, Ariz. , Oct. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017
TUCSON, Ariz. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present a corporate overview at the Cantor Fitzgerald Global Healthcare
TUCSON, Ariz. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the United States Patent and Trademark Office has issued two U.S.
Supports continued growth of HTG’s clinical diagnostic business TUCSON, Ariz. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that is has successfully
Company Intends to Submit Fourth and Final Module for PMA in Second Quarter of 2018 TUCSON, Ariz. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it
TUCSON, Ariz. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19 th Annual Global Investment Conference in
TUCSON, Ariz. , Aug. 09, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing
Provides 2017 Revenue Guidance of $9.0 million to $12.0 million TUCSON, Ariz. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the
Developing NGS Gene Expression Profiling Assays for Multiple Cancer Therapies TUCSON, Ariz. and VENLO, the Netherlands , July 27, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications
